SCHEMBL1616382

SCHEMBL1616382

CN(C)/C=C1/CCCC(N2CCOCC2)C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.38
TSHR P16473 2/20 0.35
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
ALDH1A1 P00352 9/20 0.33
HSD17B10 Q99714 3/20 0.33
POLB P06746 1/20 0.31
MAPK1 P28482 1/20 0.31
TP53 P04637 1/20 0.31
CYP2C19 P33261 2/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C9 P11712 1/20 0.31
ALOX15 P16050 1/20 0.31
CREBBP Q92793 1/20 0.31
GAA P10253 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1616383 1.00 PDE4D (0.38) PDE4DTSHRHTTSMN1; SMN2CNR1
SCHEMBL1615855 0.76 TSHR (0.35) TSHRSMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL1615856 0.76 TSHR (0.35) TSHRSMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL1617390 0.68 MAPT (0.35) HTTALDH1A1HSD17B10CYP2C19LMNA
SCHEMBL1617387 0.68 MAPT (0.35) HTTALDH1A1HSD17B10CYP2C19LMNA
SCHEMBL3665190 0.68
SCHEMBL16136808 0.68 PDE4D (0.44) PDE4DTSHRHTTSMN1; SMN2CNR1
SCHEMBL908743 0.66 SLC18A3 (0.53) PDE4DTSHRHTTSMN1; SMN2ALDH1A1
SCHEMBL1617565 0.66 NPC1 (0.42) HTTSMN1; SMN2ALDH1A1HSD17B10CYP2C19
SCHEMBL1616963 0.66 LMNA (0.32) HTTHSD17B10CYP2C19LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012030952-A3 REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY TEXAS INSTRUMENTS INCORPORATED (US) 2012-05-10 WO disclosed
EP-2231629-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2011-11-30 EP disclosed
US-7923450-B2 Modulators for amyloid beta HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2231629-A1 MODULATORS FOR AMYLOID BETA F. Hoffmann-La Roche AG (CH) 2010-09-29 EP disclosed
WO-2009087127-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 WO disclosed
US-20090181965-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181965-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, BACE1 PDE4D 842/4885TSHR 4301/4885HTT 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.